UCB S.A (UCB) | Stock Overview & Key Data
UCB S.A. | Large-cap | Healthcare
UCB S.A. | Large-cap | Healthcare
UCB S.A Performance Comparison
Stock Range
Today's Range
Low: €250.10
High: €256.90
on October 6, 2025
52 Week Range
Low: €129.35
High: €256.90
on April 9, 2025
on October 6, 2025
All-Time High: €256.90 on October 6, 2025
Explore how other BE stocks compare to their 52-week ranges: View BE Market 52-Week Insights
Key Statistics
Market Cap
€48.1B
EPS
6.85
P/E Ratio (TTM)
36.79
Forward P/E
36.73
P/B Ratio
4.94
PEG Ratio
36.73
Div. Yield
0.90%
ROE
14.30%
Beta
0.284
Debt to Equity
29.72
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
19.90%
Profit Margin
19.45%
Returns and Earnings
Return on Assets (TTM)
4.63%
Return on Equity (TTM)
14.30%
EBITDA
€1.5B
Net Income (TTM)
€1.3B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
€36.03
Quarterly Revenue Growth (YoY)
24.90%
Quarterly Earnings Growth (YoY)
128.40%
Dividend Information
Last 12-Month Dividend
€1.39
Current Dividend Yield
0.90%
3-Year Average Dividend Yield
1.19%
3-Year Average Annual Dividend
€1.36
3-Year Total Dividends
€4.08
Ex-Dividend Date
April 25, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| UCB S.A UCB | 48.11B Large-cap | 27.98% | 24.75% | 54.03% | 56.67% | 31.70% | 51.44% | 246.44% | 157.56% |
| Argenx SE ARGX | 43.16B Large-cap | 10.63% | 11.14% | 47.35% | 26.38% | 11.07% | 41.19% | 86.58% | 188.93% |
| Onward Medical N.V ONWD | 232.37M Mid-cap | 4.84% | -2.99% | 11.59% | 29.68% | -2.62% | 0.00% | -15.45% | -59.18% |
| Hyloris HYL | 167.44M Mid-cap | 2.40% | -8.84% | -4.47% | 0.34% | -6.56% | 0.34% | -53.57% | -41.03% |
| European Medical ALEMS | 23.28M Small-cap | 0.00% | 26.44% | 22.22% | 13.87% | -8.33% | -18.64% | -86.41% | -91.62% |
| Celyad Oncology S.A CYAD | 12.72M Small-cap | -16.13% | -16.13% | -29.73% | -48.00% | -61.19% | -7.14% | -79.20% | -96.79% |
Ownership & Short Interest
Insider Ownership
36.25%
Institutional Ownership
40.25%
Shares Short
N/A
Short Ratio
N/A
Short % of Shares Outstanding
N/A
Average 10-Day Volume
296K
Average 90-Day Volume
227K
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is UCB's 52-week high and low?
- In the last 52 weeks, UCB S.A reached a high of €256.90 (on October 6, 2025) and a low of €129.35 (on April 9, 2025).
- What is the market cap and P/E ratio for UCB?
- Curious about UCB S.A's size and valuation? Its market capitalization stands at 48.11B. When it comes to valuation, the P/E ratio (trailing twelve months) is 36.79, and the forward P/E (looking ahead) is 36.73.
- Does UCB pay dividends? If so, what's the yield?
- Yes, UCB S.A is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.90%, and the company has paid an average of €1.36 per share annually over the past 3 years.
- Who are UCB S.A's main competitors or similar companies to consider before investing?
When looking at UCB S.A, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Argenx SE
ARGX43.16B Healthcare Biotechnology 41.19% 86.58% Onward Medical N.V
ONWD232.37M Healthcare Biotechnology 0.00% -15.45% Hyloris
HYL167.44M Healthcare Biotechnology 0.34% -53.57% European Medical
ALEMS23.28M Healthcare Biotechnology -18.64% -86.41% Celyad Oncology S.A
CYAD12.72M Healthcare Biotechnology -7.14% -79.20% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for UCB S.A.? (e.g., ROE, Debt/Equity)
- To get a sense of UCB S.A's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 14.30%, the Debt to Equity ratio from the most recent quarter is 29.72, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for UCB?
- Looking at UCB S.A's growth, its revenue over the trailing twelve months (TTM) was €7B. Compared to the same quarter last year (YoY), quarterly revenue grew by 24.90%, and quarterly earnings saw a YoY growth of 128.40%.
- How much of UCB stock is held by insiders and institutions?
- Wondering who owns UCB S.A stock? Company insiders (like executives and directors) hold about 36.25% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 40.25%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.